secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001193125-25-180313
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director Michael Davidson resigns from Silence Therapeutics board
-----------------------------------------------------------------

- Davidson resigned as director effective August 11, 2025, citing need to focus on other time commitments.
- He also stepped down from Audit, Risk, Remuneration, and Science & Technology Committees.
- Board reduced from five to four members; Iain Ross appointed to Audit and Risk Committee.
- Davidson remains CEO of NewAmsterdam Pharma; resignation not due to any disagreement with the Company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525180313/0001193125-25-180313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525180313/d68551d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-180313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer